Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of a sustained-exposure formulation of gacyclidine (OTO-311) as a potential therapy for tinnitus.

Next Previous
Trial Profile

Phase I trial of a sustained-exposure formulation of gacyclidine (OTO-311) as a potential therapy for tinnitus.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gacyclidine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions
  • Sponsors Otonomy [CEASED]

    • Most Recent Events

    • 02 Mar 2017 According to an Otonomy media release, status changed from recruiting to completed.
    • 03 Nov 2016 According to an Otonomy media release, several dose cohorts in the trial have been completed without patient tolerability concerns and the trial will remain open into 2017 pending the potential evaluation of additional dose levels in order to establish a maximum tolerated dose.
    • 16 Nov 2015 This trial is expected to be completed in the first half of 2016, according to an Otonomy media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top